Self-Study 2026: Neuroendocrine Tumors

Type: Individual•Format: On-demand

Current neuroendocrine tumor (NET) treatment options vary for patients including systemic chemotherapy, radionuclide therapy, oral oncolytics, and more. Notably, recent therapeutic advancements, such as with 77Lu-Dotatate (Lutathera) and cabozantinib, have expanded treatment strategies. This module delves into neuroendocrine tumor classification, while exploring complications such as carcinoid syndrome. This module also discusses advancements in therapeutic options for NET patients, with a focus on the CABINET and NETTER-2 clinical trials, while evaluating the safety and efficacy of these agents.

Neuroendocrine Tumors

Author: Meera J. Patel, PharmD, BCOP - Oncology Clinical Pharmacy Specialist

Learning Objectives

  1. Recognize the degree of differentiation, grading, and location of neuroendocrine tumors to help guide treatment
  2. Understand Carcinoid syndrome and existing agents for symptomatic control of neuroendocrine tumors
  3. Apply current treatment regimens and emerging agents for treatment of extrapancreatic and pancreatic neuroendocrine tumors
  4. Differentiate adverse events and toxicity profiles of neuroendocrine tumor agents, including 177Lu-Dotatate (Lutathera) and cabozantinib

Get it here

Application Course for Pharmacists

Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

acpe-bps-logos

HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post-Test with a 75% or higher.

All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.